Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2301 to 2310 of 2579 total matches.

Pipecuronium - A New Neuromuscular Blocker

   
The Medical Letter on Drugs and Therapeutics • Dec 14, 1990  (Issue 833)
or omission. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB ...
Pipecuronium bromide (Arduan - Organon), a long-acting, non-depolarizing neuromuscular agent chemically related to pancuronium (Pavulon; and others), is now available in the USA for use as a skeletal muscle relaxant during general anesthesia and for endotracheal intubation. It is not recommended for procedures that last less than 90 minutes or for patients requiring prolonged mechanical ventilation in intensive care units.
Med Lett Drugs Ther. 1990 Dec 14;32(833):114 |  Show IntroductionHide Introduction

Betaine for Homocystinuria

   
The Medical Letter on Drugs and Therapeutics • Jan 31, 1997  (Issue 993)
. Copyright  1988-2002. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http ...
Betaine (Cystadane - Orphan Medical), an orphan drug, has recently been marketed for treatment of homocystinuria, a genetic disorder. Patients with homocystinuria frequently have premature atherosclerosis and thromboembolism, and may also have lens dislocations, skeletal abnormalities and mental retardation (SH Mudd et al in CR Scriver et al, eds, The Metabolic and Molecular Bases of Inherited Disease, 7th ed, New York:McGraw Hill, 1995, page 1279).
Med Lett Drugs Ther. 1997 Jan 31;39(993):12 |  Show IntroductionHide Introduction

The Crystal Ear Hearing Aid

   
The Medical Letter on Drugs and Therapeutics • Jun 05, 1998  (Issue 1028)
. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com The Medical Letter, Vol ...
Full-page advertisements in The New York Times and other newspapers have promoted use of the Crystal Ear hearing aid as an inexpensive rememdy for people with impaired hearing. Some patients may be asking their physicians about these devices.
Med Lett Drugs Ther. 1998 Jun 5;40(1028):62 |  Show IntroductionHide Introduction

A Percutaneous Device (MitraClip) for Mitral Regurgitation

   
The Medical Letter on Drugs and Therapeutics • Dec 23, 2013  (Issue 1432)
surgery for mitral valve dysfunction.1 At 4 years, the primary composite endpoint persisted in 40 ...
The FDA has approved the use of a transcatheter mitral valve device (MitraClip – Abbott) for percutaneous treatment of significant symptomatic degenerative mitral regurgitation (grade 3-4+) in patients who are at prohibitive risk for mitral valve surgery. It is the first percutaneous nonsurgical treatment approved for this indication.
Med Lett Drugs Ther. 2013 Dec 23;55(1432):103-4 |  Show IntroductionHide Introduction

Durlaza - A 24-Hour Extended-Release Aspirin

   
The Medical Letter on Drugs and Therapeutics • Jan 18, 2016  (Issue 1486)
at the end of the 24-hour dosing interval.1 An ER formulation that releases acetylsalicylic acid (ASA) over ...
The FDA has approved Durlaza (New Haven Pharmaceuticals), a 24-hour extended-release (ER) aspirin formulation available only by prescription, for secondary prevention of myocardial infarction (MI) and stroke.
Med Lett Drugs Ther. 2016 Jan 18;58(1486):7 |  Show IntroductionHide Introduction

Table: Over the Counter At-Home Tests for COVID-19 (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 20, 2021  (Issue 5041)
Overall: 92%/98% No Yes6 75.00 Test Kit (Lucira) minutes Symptomatic: 94%/98% (1 ct)7 Asymptomatic: 90 ...
View the Table: Over the Counter At-Home Tests for COVID-19
Med Lett Drugs Ther. 2021 Oct 20;63(5041):e1   doi:10.58347/tml.2021.5041a |  Show IntroductionHide Introduction

Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 03, 2025  (Issue 1721)
) 5.8 g/teaspoon powder; 5.8 g packets; 1.8 g caps; 2 g wafers $29.00 10-35 g/day in 2-3 divided ...
View the Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C)
Med Lett Drugs Ther. 2025 Feb 3;67(1721):e1-3   doi:10.58347/tml.2025.1721e |  Show IntroductionHide Introduction

Smallpox Vaccine

   
The Medical Letter on Drugs and Therapeutics • Jan 06, 2003  (Issue 1147)
) FORWARDING OR COPYING IS A VIOLATION OF U.S. AND INTERNATIONAL COPYRIGHT LAWS 1 Vaccination — Smallpox ...
Because of concerns about the possibility of bioterrorism involving smallpox, the US government is reinstituting smallpox vaccination (https://www.cdc.gov/smallpox/; www.idsociety.org/bt/toc.htm). Vaccination is currently expected to proceed in three phases: the military and hospital smallpox response teams first, other health care workers, police and firefighters second, and the general public in the third phase. Except for the military, vaccination will be...
Med Lett Drugs Ther. 2003 Jan 6;45(1147):1-3 |  Show IntroductionHide Introduction

Alendronate and Risedronate

   
The Medical Letter on Drugs and Therapeutics • Apr 25, 2005  (Issue 1207)
% of the alendronatetreated women. 1 After 5 years, placebo-treated patients were discharged from the study. Patients ...
A 10-year study of daily oral alendronate (Fosamax) and a 7-year study of daily oral risedronate (Actonel) indicate that both drugs maintained increases in bone mineral density (BMD) and decreases in markers of bone remodeling throughout the study period. Both drugs are now more commonly taken once weekly. Available data are insufficient to compare fracture rates with alendronate and risedronate, and fracture rates are considered the most important endpoint in osteoporosis studies. Recent reports of severe pain and jaw osteonecrosis with these drugs are disturbing.
Med Lett Drugs Ther. 2005 Apr 25;47(1207):33-5 |  Show IntroductionHide Introduction

Dasatinib (Sprycel) for CML and Ph+ ALL

   
The Medical Letter on Drugs and Therapeutics • Jan 15, 2007  (Issue 1252)
of CML, was approved by the FDA in 2001. 1 It is now the standard first-line treatment for all stages ...
Dasatinib (Sprycel - Bristol-Myers Squibb), an inhibitor of multiple tyrosine kinases, has been approved by the FDA for second-line treatment of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in adults.
Med Lett Drugs Ther. 2007 Jan 15;49(1252):6-7 |  Show IntroductionHide Introduction